5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羧酸 | 103031-30-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羧酸
• 英文名称: 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxylic acid
• 英文别名: 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoic acid；5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenecarboxylic acid；5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid；5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carboxylic acid
• CAS: 103031-30-7
• 化学式: C₁₅H₂₀O₂
• mdl: MFCD04115382
• 分子量: 232.323
• InChiKey: KSEZYZSBKCPEKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.533
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2916399090
• 储存条件：
  存储条件：室温、密封、干燥

SDS

Name:	5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenecarboxylic acid Material Safety Data Sheet
Synonym:	None Known.
CAS:	103031-30-7

Section 1 - Chemical Product MSDS Name: 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenecarboxylic acid Material Safety Data Sheet
Synonym: None Known.

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
103031-30-7	5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro	97+	unlisted

+++++
Hazard Symbols: XI

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 103031-30-7: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: white
Odor: slight
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 197-199 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H20O2
Molecular Weight: 232

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 103031-30-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenecarboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 22 Do not breathe dust. S 24/25 Avoid contact with skin and eyes. S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 36/37/39 Wear suitable protective clothing, gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 103031-30-7: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 103031-30-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 103031-30-7 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 5/19/2004 Revision #1 Date: 5/19/2004 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羧酸 在 4-二甲氨基吡啶 、 sodium hydroxide 、 氯化亚砜 作用下， 以 乙醇 为溶剂， 反应 2.5h， 生成 4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)甲酰氨基]苯甲酸
  参考文献：
  名称：

  视黄苯甲酸。1.芳族酰胺与类视色素活性的结构-活性关系。

  摘要：

  已显示两种类型的芳族酰胺，对苯二甲酸单苯胺和（芳基甲酰胺基）苯甲酸具有有效的类维生素A活性，可以归类为类维生素A。基于对人早幼粒细胞白血病细胞HL-60的分化诱导活性，讨论了这些酰胺的构效关系。在通式4（X ＝ NHCO或CONH）中，引起类视色素活性的必要因素是在其间位的中等尺寸烷基（异丙基，叔丁基等）和在其对位的羧基。另一个苯环。酰胺结构的键可以颠倒，该部分显然具有将两个苯环相对于彼此定位在适当位置的作用。推测是由于所得的构象变化，在酰胺基邻位的环位置取代或酰胺基的N-甲基化导致活性降低。显然，苄基甲基和羧基的相互取向以及它们之间的距离是决定类视色素活性的必要因素。在合成的化合物中，4-[（（5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基）氨基甲酰基]苯甲酸（Am80）和4-[（5,6，在该测定中，7,8-四氢-5,5,8,8-四甲基-2-萘基[羧酰胺基]苯甲酸（Am580）的

  DOI：

  10.1021/jm00119a021
• 作为产物：
  描述：

  甲苯 在 sodium hydroxide 、 potassium permanganate 、 三氯化铝 作用下， 以 吡啶 为溶剂， 生成 5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羧酸
  参考文献：
  名称：

  Isolation and Proof of Structure of 1,1,4,4-Tetramethyl-6-t-butyl-1,2,3,4- tetrahydronaphthalene¹

  摘要：

  DOI：

  10.1021/jo01075a008

文献信息

• 一种维甲酸类衍生物Am580的合成方法
  申请人：成都大学

  公开号：CN112479918B

  公开（公告）日：2023-07-14

  本发明公开了一种维甲酸类衍生物Am580的合成方法，该方法包括以下步骤：将2,5‑二甲基己烷‑2,5‑二醇在浓HCl中的溶液搅拌30min，后向体系里通入HCl气体反应3h，后搅拌至体系变成两相混合物，冷却至室温，过滤得浅粉红色固体，用水洗涤，在甲醇中重结晶后过滤得到中间体3，产物为白色固体，将2,5‑二氯‑2,5‑二甲基己烷溶解在有机溶剂中，将AlCl3加入到溶液中，所述2,5‑二氯‑2,5‑二甲基己烷与AlCl3的摩尔比为1:0.1‑1:0.2，加热至100‑120℃搅拌16h后用3M HCl淬灭反应，并用正己烷萃取，减压蒸馏除去溶剂得到产物为无色油状物中间体4。本发明的有益效果是：本发明每步收率较高，后处理简单，更加易于工业化生产；本发明针对傅克反应以及氧化反应优化反应条件以及溶剂体系，更有利于工业化生产。
• Di(aromatic) compounds and their use in human and veterinary medicine
  申请人：Centre International de Recherches Dermatologiques Galderma (Cird

  公开号：US05387594A1

  公开（公告）日：1995-02-07

  Di(aromatic) compounds corresponding to the following formula: ##STR1## in which: Ar represents either ##STR2## n=1 or 2 or: ##STR3## X represents a divalent radical, Z represents O, S or a divalent radical, and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 represent a hydrogen atom or various organic radicals, and the salts of the compounds of formula (I) when R.sub.1 is a carboxylic acid function. Use in human and veterinary medicine and in cosmetics.

  对应以下公式的二芳基化合物：##STR1## 其中：Ar代表##STR2## n=1或2或：##STR3## X代表二价基团，Z代表O、S或二价基团，R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5代表氢原子或各种有机基团，以及当R.sub.1是羧酸功能时，公式（I）化合物的盐。用于人类和兽医学以及化妆品。
• Antitumor Activity of 5-Aryl-2,3-dihydroimidazo[2,1-a]isoquinolines
  作者：William J. Houlihan、Paul G. Munder、Dean A. Handley、Seung H. Cheon、Vincent A. Parrino

  DOI：10.1021/jm00002a004

  日期：1995.1

  A series of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines previously reported to be platelet activating factor (PAF) receptor antagonists were evaluated for potential antitumor activity. Several compounds, such as the 5-(4'-tert-butylphenyl) (65), 5-[4'-(trimethylsilyl)phenyl] (69), and 5-(4'-cyclohexylphenyl) (71) analogs showed very good cytotoxicity against several tumor cell lines. 5-[4'-(Pipe

  评估了一系列先前报道为血小板活化因子（PAF）受体拮抗剂的5-芳基-2,3-二氢咪唑并[2,1-a]异喹啉的潜在抗肿瘤活性。几种化合物，例如5-（4'-叔丁基苯基）（65），5- [4'-（三甲基甲硅烷基）苯基]（69）和5-（4'-环己基苯基）（71）类似物显示出对几种肿瘤细胞系具有良好的细胞毒性。5- [4'-（哌啶子基甲基）苯基] -2,3-二氢咪唑并[2,1-a]异喹啉（SDZ 62-434，53）在毫克每千克的基础上比临床细胞生长抑制剂edelfosine更有效（1 ）在口服小鼠Meth A纤维肉瘤试验中增加存活率并减少肿瘤体积。它被选作进一步开发，目前正在癌症患者的I期临床试验中。
• Retinoidal Pyrimidinecarboxylic Acids. Unexpected Diaza-Substituent Effects in Retinobenzoic Acids.
  作者：Kiminori OHTA、Emiko KAWACHI、Noriko INOUE、Hiroshi FUKASAWA、Yuichi HASHIMOTO、Akiko ITAI、Hiroyuki KAGECHIKA

  DOI：10.1248/cpb.48.1504

  日期：——

  Several pyridine-and pyrimidine-carboxylic acids were synthesized as ligand candidates for retinoid nuclear receptors, retinoic acid receptors (RARs) and retinoic X receptors (RXRs). Although the pyridine derivatives, 6-[(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)carbamoyl]pyridine-3-carboxylic acid (2b) and 6-[(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)carboxamido]pyridine-3-carboxylic acid (5b) are more potent than the corresponding benzoic acid-type retinoids, Am80 (2a) and Am580 (5a), the replacement of the benzene ring of Am580 (5a), Am555 (6a), or Am55 (7a) with a pyrimidine ring caused loss of the retinoidal activity both in HL-60 cell differentiation assay and in RAR transactivation assay using COS-1 cells. On the other hand, pyrimidine analogs (PA series, 10 and 11) of potent RXR agonists (retinoid synergists) with a diphenylamine skeleton (DA series, 8 and 9) exhibited potent retinoid synergistic activity in HL-60 cell differentiation assay and activated RXRs. Among the synthesized compounds, 2-[N-n-propyl-N-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)amino]pyrimidene-5-carboxylic acid (PA013, 10e) is most active retinoid synergist in HL-60 assay.

  几种吡啶和嘧啶羧酸被合成为视黄酸核受体、视黄酸受体（RARs）和视黄酸X受体（RXRs）的配体候选物。虽然吡啶衍生物，6-[(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)氨基甲酰]吡啶-3-羧酸（2b）和6-[(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)羧酰胺]吡啶-3-羧酸（5b）比相应的苯甲酸型视黄酸更有效，如Am80（2a）和Am580（5a），但将Am580（5a）、Am555（6a）或Am55（7a）的苯环替换为嘧啶环会导致视黄酸活性在HL-60细胞分化试验和使用COS-1细胞的RAR转录激活试验中丧失。另一方面，具有二苯胺骨架（DA系列，8和9）的强效RXR激动剂（视黄酸协同剂）的嘧啶类似物（PA系列，10和11）在HL-60细胞分化试验中表现出强效的视黄酸协同活性并激活RXRs。在合成的化合物中，2-[N-正丙基-N-(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)氨基]嘧啶-5-羧酸（PA013，10e）在HL-60试验中是最活跃的视黄酸协同剂。
• RETINOID PRODRUG COMPOUND
  申请人：Muratake Hideaki

  公开号：US20100286427A1

  公开（公告）日：2010-11-11

  A compound represented by the following general formula (I): [R 1 to R 5 represent hydrogen atom, an alkyl group, or a trialkylsilyl group, X represents —NH—CO—, —CO—NH—, —N(COR 6 )—CO—, —CO—N(COR 7 )— (R 6 and R 7 represent a lower alkoxy group, or a carboxy-substituted phenyl group) etc.; and Z represents —Y—CH(R 12 )—COOH, —CHO, —CH═CH—COOH, or —COOR 13 (Y represents a single bond, —CH 2 —, —CH(OH)—, —CO—, —CO—NH—, or —CO—NH—CH 2 —CO—NH—, R 12 represents hydrogen atom or a lower alkyl group, and R 13 represents hydrogen atom, —CH(R 14 )—COOH(R 14 represents hydrogen atom, a lower alkyl group, or hydroxy group), —[CH 2 CH 2 —O] n —CH 2 —CH 2 —OH, —CH 2 —O—[CH 2 CH 2 —O] m —CH 2 —OH, or —[CH(CH 3 )—CO—O] p —CH(CH 3 )—COOH (m, n and p represent an integer of 1 to 100))], a salt thereof or an ester thereof, which has a property of being converted into a retinoid after absorption in vivo.

  由以下一般式（I）表示的化合物： [R1至R5代表氢原子、烷基或三烷基硅基，X代表—NH—CO—、—CO—NH—、—N(COR6)—CO—、—CO—N(COR7)—（R6和R7代表较低的烷氧基或羧基取代的苯基）等；Z代表—Y—CH(R12)—COOH、—CHO、—CH═CH—COOH或—COOR13（Y代表单键、—CH2—、—CH(OH)—、—CO—、—CO—NH—或—CO—NH—CH2—CO—NH—，R12代表氢原子或较低的烷基，R13代表氢原子、—CH(R14)—COOH（R14代表氢原子、较低的烷基或羟基），—[CH2CH2—O]n—CH2—CH2—OH、—CH2—O—[CH2CH2—O]m—CH2—OH或—[CH(CH3)—CO—O]p—CH(CH3)—COOH（m、n和p代表1至100的整数）]，其盐或酯，具有在体内吸收后转化为视黄醇类物质的特性。